CM
EWTX icon

Caption Management’s Edgewise Therapeutics EWTX Stock Holding History

Caption Management’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-38,675
Closed -$1.33M – 1786
2026
Q1 		$1.22M Buy
+38,675
New +$1.12M 0.01% 956
2025
Q2 		– Sell
-204,500
Closed -$4.5M – 1597
2025
Q1 		$4.5M Buy
+204,500
New +$5.36M 0.04% 424

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Caption Management's EWTX Position: Q2 2026 in Review

Caption Management sold out of Edgewise Therapeutics (EWTX) in Q2 2026, closing a stake of 38,675 shares — an estimated $1.33M sold.

Caption Management first reported a position in EWTX in Q1 2025 and held it in 2 quarters. The position peaked at $4.5M in Q1 2025. 226 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Caption Management reported no remaining Edgewise Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Caption Management sold 38,675 Edgewise Therapeutics shares in Q2 2026, an estimated $1.33M.
  • Caption Management first reported a position in Edgewise Therapeutics in Q1 2025 and held it in 2 quarters.
  • Caption Management's Edgewise Therapeutics position peaked at $4.5M in Q1 2025.
  • 226 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Caption Management's 13F filing for Q2 2026, filed 14 Aug 2026.